A clinical trial on Conbercept for macular edema secondary to central retinal vein occlusion

AIM: To investigate the effect and safety of intravitreous injection of conbercept(0.5mg)on macular edema secondary to central retinal vein occlusion(CRVO). METHODS: According to the selective criteria, from October 2014 to October 2015, 48 cases(48 eyes)of patients with macular edema secondary to CRVO were collected, which were divided randomly into conbercept group(24 cases, 24 eyes)and control group(triamcinolone acetonide 4mg/0.1mL, 24 cases,24 eyes). The best-corrected visual acuity(BCVA), intraocular pressure, intravitreous injection, fundus oculi, central macular thickness(CMT)and related complications were observed before and 1wk, 1, 3, 6 and 12mo after intravitreous injection. RESULTS: There was no difference on BCVA, intraocular pressure, intravitreous injection, fundus oculi and CMT between the two groups before operations(P>0.05). There were no significant differences(P>0.05)of the BCVA between two groups after treatment for 1wk, 1, 3, 6 and 12mo. Before and after treatment, the decrease of CMT in conbercept group was respectively 130.17±1.72μm, 253.33 ±3.14μm, 318.00±1.41μm, 20.01±1.21μm and 15.09±1.41μm, and no related complications. The decrease of CMT in control group was respectively 132.5±2.07μm, 249.67±1.21μm, 317.50±4.23μm, 18.01±1.41μm and 16.09±1.31μm, and no related complications. There were no significant differences(F=6.882, P=0.663>0.05)of CMT between two groups after treatment for 1wk, 1, 3, 6 and 12mo. Injection times were respectively 2.83±0.72 and 3.17±0.71 in control group and conbercept group, and the difference between two groups has no statistical significance(P>0.05). There were 4 cases(17%)of paracentesis of anterior chamber, 3 cases(13%)of intraocular hypertension and 1 case(4%)of complicated cataract in control group. There was no related complications in conbercept group.CONCLUSION: Intravitreous injection of conbercept for macular edema secondary to CRVO is effective, safe and less complications.